NVO
🤷 The speaker explicitly states a lack of confidence in investing in Novo Nordisk due to being an ‘ignorant’ regarding the complex competitive landscape of weight-loss drugs.
💊 Mention is made of key competitors like Eli Lilly, Pfizer (which reportedly had issues with its pill), and Viking Therapeutics, highlighting the dynamic and challenging nature of the industry.
🚫 Consequently, the speaker assigns a ‘zero’ probability to buying Novo Nordisk shares currently, preferring industries where they feel more informed, despite acknowledging the stock’s potential.
@bernardodegarcia:
“Interesting, Novo Nordisk. I would find it interesting to analyze it deeply, but an entry right now… Novo Nordisk, if you ask me, Bernardo, from zero to 10, what are the chances that you will enter or buy shares of Novo Nordisk? Zero. Absolutely zero. And maybe I’ll regret it, but right now, absolutely zero. Why? Because I don’t know. Ah, I am ignorant regarding the depth of the current situation of Novo Nordisk, of Eli Lilly, of all its competitors. Today Pfizer said it messed up a bit with its pill and was no longer working on it. Then there’s Viking Therapeutics, which is… I mean, it’s a world that seems fascinating to me because I’m very outside of it, okay? There are many other companies where, well, I’m a bit more in tune with the market or with the industry, rather, and that I like more and see more potential in. Novo, I perhaps see a lot of potential, but eh, I don’t have much certainty.”
Watch the exact part of the video where @bernardodegarcia talks about Novo Nordisk here:
Watch the video on YouTube
Read more articles analyzing Novo Nordisk (NVO) at the provided link. NVO stock.
